Skip to content Skip to main menu Skip to utility menu

Drug safety notice: Emergency prohibition of dupply of GnRH analogues 

June 3, 2024

There is now new restrictions to prohibit the prescribing of GnRH analogues as puberty blockers to patients under 18 years of age.

This does not apply if the patient has already commenced treatment and/or is part of an NIHR-supported clinical trial.

Restrictions apply to health service (NHS) and independent (private) prescribing.

This is an emergency legislation; the prohibition will occur until Tuesday 3 September.

Advice/actions:

  • During this period no new patients under the age of 18 years will be prescribed these medicines for any purposes of puberty suppression in those experiencing genre dysphoria or incongruence under the care of any prescriber.
  • The government has also introduced indefinite restrictions on prescribing these medicines within NHS primary care in England, in line with NHS guidelines.
  • The new arrangements apply to gonadorelin, goserelin, leuprorelin acetate, nafarelin or triptorelin.
  • They will remain available from a UK-registered prescriber for patients receiving these drugs for other uses.

For more information please see the Drug Safety Notice.

If you have any questions please contact the pharmacy department on ext. 5263/3783.